Rebound Effect in the Misight Assessment Study Spain (Mass)

Ruiz-Pomeda, Alicia; Garrido, F. Prieto; Hernández-Verdejo, José Luis; Villa-Collar, César

doi:10.1080/02713683.2021.1878227

Cited by 21 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, 41% of patients in the MiSight group had no progression in spherical equivalent refraction. In another trial, no rebound effect was observed for MiSight lenses after one year [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although we are still waiting for an evidence-based treatment algorithm for myopia, some strategies have shown a variable effectiveness in slowing its progression. These include more time spent outdoors [ 9 , 10 ], progressive addition lenses spectacles (PALs) [ 9 , 11 , 12 ], prismatic bifocal lenses spectacles (PBLs) [ 9 , 13 ], defocus spectacle lenses [ 14 ], soft contact lenses (SCLs) [ 9 , 15 , 16 , 17 , 18 , 19 , 20 ], orthokeratology (OK) [ 9 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ], and various concentrations of antimuscarinic eye drops, mainly atropine, cyclopentolate, and pirenzepine [ 9 ]. These strategies are sometimes combined in order to increase their efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Atropine in Preventing Myopia Progression: An Update

et al. 2022

View full text Add to dashboard Cite

Several approaches have been investigated for preventing myopia progression in children and teenagers. Among them, topical atropine has shown promising results and it is being adopted in clinical practice more and more frequently. However, the optimal formulation and treatment algorithm are still to be determined. We discuss the pharmacokinetic, pharmacodynamic, clinical, and tolerability profile revealed first by the multicenter, randomized ATOM 1 and 2 trials and, more recently, by the LAMP Study. Results from these trials confirmed the efficacy of low-concentration atropine with a concentration-dependent response. Although atropine at 0.025% and 0.05% concentrations has shown the most encouraging results in large-scale studies, these formulations are not yet commonplace in worldwide clinical practice. Moreover, their rebound effect and the possibility of reaching a stabilization effect have not been fully investigated with real-life studies. Thus, further larger-scale studies should better characterize the clinical efficacy of atropine over longer follow-up periods, in order to define the optimal dosage and treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Role of Atropine in Preventing Myopia Progression: An Update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Compared with two long-term effective myopia control MSCLs, the MiSight [7,36] and defocused incorporated soft contact (DISC) lenses [6], the lenses used in this study had a larger central zone (MiSight, 3.36 mm; DISC, 3 mm; vs. current study, 6 mm) and a higher add power (MiSight, + 2.0 D; DISC, + 2.5 D; vs. current study, + 8 to + 20 D) [6,28,30]. Thus, there are two conjectures about lens design to explain the ineffectiveness of the MSCL in this study.…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis showed OK lenses could slow myopia progression by approximately 30% to 60% [4]. Another efficient method that is widely recognized is bifocal (BSCL) or multifocal soft contact lenses (MSCL) [5][6][7]. These are commonly designed for central distance correction and peripheral additions.…”

Section: Introductionmentioning

confidence: 99%

Comparison of peripheral refraction and higher-order aberrations between orthokeratology and multifocal soft contact lens designed with highly addition

Huang

Xue

Ding

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To compare peripheral defocus, higher-order aberrations (HOAs), and contrast visual acuity (CVA) in myopic children wearing orthokeratology (OK) lenses and multifocal soft contact lenses (MSCLs) designed with highly addition. Methods This is a prospective, nonrandomized, controlled study. Subjects at 8 to 13 years of age with spherical equivalent refraction from − 1.00 to − 5.00 dioptres (D) were included in the OK group (n = 30) and MSCL group (n = 23). Relative peripheral corneal defocus (RPCD) and relative peripheral refraction (RPR) were measured before and after wearing lenses. HOAs including spherical aberration (SA), coma, trefoil, and total HOAs, and high (100%) and low (10%) CVA were compared between the groups. Axial length (AL) was measured before and after wearing the lenses for 1 year. Results After wearing the lenses, subjects in the MSCL group had RPCD and RPR values similar to the OK group at the paracentral (within 2 mm of the cornea or 20° of the retina, all p > 0.05) but larger than the OK group at the periphery (all p < 0.05). All HOAs increased after wearing the lenses except the trefoil in the MSCL group (all p < 0.05). HOAs increased more in the OK group (all p < 0.05). The 100% and 10% CVAs were worse in the MSCL group (p = 0.02 and p = 0.004). After 1 year, AL elongation was 0.37 mm (SD = 0.16) in the MSCL group and 0.28 mm (0.16) in the OK group (p = 0.06). Conclusion MSCL produced larger myopic defocus at the periphery, increased less HOAs and had worse CVA than OK lens. The high addition of this MSCL did not result in better myopia control efficacy Trial registration Chinese Clinical Trial Registry: ChiCTR1800018564. Registered 25 September 2018; retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=31376

show abstract

“…Dramatic post-treatment acceleration, or rebound, has been reported with 1% atropine, but does not seem to occur with spectacle 35 or soft contact lens therapies. 75,153 Nonetheless, some level of rebound should be assumed until proven otherwise. 93 The choice of treatment will be ultimately be determined by a discussion among practitioner, parent, and patient, but influenced by regional practice patterns and scope of practice.…”

Section: Limitations Of Modelmentioning

confidence: 99%

The Risks and Benefits of Myopia Control

et al. 2021

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Rebound Effect in the Misight Assessment Study Spain (Mass)

Cited by 21 publications

References 12 publications

The Role of Atropine in Preventing Myopia Progression: An Update

The Role of Atropine in Preventing Myopia Progression: An Update

Comparison of peripheral refraction and higher-order aberrations between orthokeratology and multifocal soft contact lens designed with highly addition

The Risks and Benefits of Myopia Control

Contact Info

Product

Resources

About